225Ac-PSMA-617靶向α治疗转移性去势抵抗性前列腺癌:泳者图分析提示肿瘤控制持续时间方面的疗效
回顾性分析40例转移性去势抵抗性前列腺癌患者,接受三个周期225Ac-PSMA-617(每2个月100 kBq/kg)治疗。38例存活至少8周的患者中,24例(63%)PSA下降超过50%,33例(87%)出现任何程度的PSA反应;末线治疗中位肿瘤控制持续时间为9.0个月,5例持续缓解超过2年。口干是停药或拒绝追加给药的主要原因之一。
要点
- 38例可评估患者中24例(63%)PSA下降超过50%,33例(87%)出现任何程度PSA反应。
- 225Ac-PSMA-617末线治疗中位肿瘤控制持续时间9.0个月,5例持续缓解超过2年。
- 口干与无反应同为停药或拒绝追加给药的主要原因,提示可能需要进一步调整方案以改善副作用。
核心结论
- 替代指标的阳性反应表明225Ac-PSMA-617具有显著的抗肿瘤活性。
- 泳者图分析提示肿瘤控制持续时间令人期待,尤其考虑到所选晚期患者的不良预后特征。
- 口干是患者停止治疗或拒绝追加给药的主要原因之一,与无反应处于同一维度,提示可能需要进一步修改治疗方案以改善副作用,从而拓宽治疗窗。
研究设计与样本
- 回顾性分析40例转移性去势抵抗性前列腺癌患者,接受三个周期225Ac-PSMA-617治疗,每2个月100 kBq/kg。
- 每4周测量前列腺特异性抗原(PSA)和血细胞计数;基线和第6个月随访时行PSMA PET/CT或PSMA SPECT/CT。
- 随访包括PSA反应持续时间和第6个月影像学无进展生存期;回顾既往治疗线持续时间,采用泳者图进行个体内比较。
主要发现
- 40例中31例按方案完成治疗;5例因无反应停止治疗,4例因口干停止治疗。
- 38例存活至少8周的患者中,24例(63%)PSA下降超过50%,33例(87%)出现任何程度的PSA反应。
- 225Ac-PSMA-617末线治疗的中位肿瘤控制持续时间为9.0个月;5例持续缓解超过2年。
- 最常见的既往一线、二线、三线、四线治疗分别为阿比特龙(中位持续时间10.0个月)、多西他赛(6.5个月)、恩扎卢胺(6.5个月)、卡巴他赛(6.0个月)。
关键数值与推荐
- 225Ac-PSMA-617给药方案为三个周期,每2个月100 kBq/kg。
- PSA反应评估:38例存活至少8周患者中24例(63%)PSA下降超过50%,33例(87%)出现任何程度PSA反应。
- 末线225Ac-PSMA-617治疗中位肿瘤控制持续时间9.0个月,5例持续缓解超过2年。
- 既往治疗中位持续时间:阿比特龙10.0个月、多西他赛6.5个月、恩扎卢胺6.5个月、卡巴他赛6.0个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of this evaluation was to identify the first indicators of efficacy for 225Ac-labeled prostate-specific membrane antigen (PSMA)-617 therapy in a retrospectively analyzed group of patients. Methods: Forty patients with metastatic castration-resistant prostate cancer were selected for treatment with three 100 kBq/kg cycles of 225Ac-PSMA-617 at 2-mo intervals. Prostate-specific antigen (PSA) and blood cell count were measured every 4 wk. PSMA PET/CT or PSMA SPECT/CT were used for baseline staging and imaging follow-up at month 6. Follow-up included the duration of PSA response and radiologic progression-free survival at month 6. Patient histories were reviewed for the duration of previous treatment lines, and a swimmer plot was used to intraindividually compare the duration of tumor control by PSMA therapy versus prior treatment modalities. Results: Thirty-one of 40 patients were treated per protocol. Five patients discontinued treatment because of nonresponse, and 4 because of xerostomia. Of the 38 patients surviving at least 8 wk, 24 (63%) had a PSA decline of more than 50%, and 33 (87%) had a PSA response of any degree. The median duration of tumor control under 225Ac-PSMA-617 last-line therapy was 9.0 mo; 5 patients had an enduring response of more than 2 y. Because all patients had advanced disease, this result compares favorably with the tumor control rates associated with earlier-phase disease; the most common preceding first-, second-, third-, and fourth-line therapies were abiraterone (median duration 10.0 mo), docetaxel (6.5 mo), enzalutamide (6.5 mo), and cabazitaxel (6.0 mo), respectively. Conclusion: A positive response for surrogate parameters demonstrates remarkable antitumor activity for 225Ac-PSMA-617. Swimmer-plot analysis indicates a promising duration of tumor control, especially considering the unfavorable prognostic profile of the selected advanced-stage patients. Xerostomia was the main reason patients discontinued therapy or refused additional administrations and was in the same dimension as nonresponse; this finding indicates that further modifications of the treatment regimen with regard to side effects might be necessary to further enhance the therapeutic range.
引用
- Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control. J Nucl Med. 2018. PMID: 29326358. doi:10.2967/jnumed.117.203539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。